Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7790121 in Advanced MASH Liver Fibrosis
NCT06903065Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2025
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of afimkibart in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Roche. Primary endpoint: Percentage of Participants with Adverse Events at 52 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06903065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903065.